Biochemical and biological characterization of exosomes containing prominin-1/CD133 by Germana Rappa et al.
Rappa et al. Molecular Cancer 2013, 12:62
http://www.molecular-cancer.com/content/12/1/62RESEARCH Open AccessBiochemical and biological characterization of
exosomes containing prominin-1/CD133
Germana Rappa1, Javier Mercapide1, Fabio Anzanello1, Robert M Pope2 and Aurelio Lorico1*Abstract
Exosomes can be viewed as complex “messages” packaged to survive trips to other cells in the local
microenvironment and, through body fluids, to distant sites. A large body of evidence indicates a pro-metastatic
role for certain types of cancer exosomes. We previously reported that prominin-1 had a pro-metastatic role in
melanoma cells and that microvesicles released from metastatic melanoma cells expressed high levels of
prominin-1. With the goal to explore the mechanisms that govern proteo-lipidic-microRNA sorting in cancer
exosomes and their potential contribution(s) to the metastatic phenotype, we here employed prominin-1-based
immunomagnetic separation in combination with filtration and ultracentrifugation to purify prominin-1-expressing
exosomes (prom1-exo) from melanoma and colon carcinoma cells. Prom1-exo contained 154 proteins, including all
of the 14 proteins most frequently expressed in exosomes, and multiple pro-metastatic proteins, including CD44,
MAPK4K, GTP-binding proteins, ADAM10 and Annexin A2. Their lipid composition resembled that of raft
microdomains, with a great enrichment in lyso-phosphatidylcholine, lyso-phosphatidyl-ethanolamine and
sphingomyelin. The abundance of tetraspanins and of tetraspanin-associated proteins, together with the high levels
of sphingomyelin, suggests that proteolipidic assemblies, probably tetraspanin webs, might be the essential
structural determinant in the release process of prominin-1 of stem and cancer stem cells. Micro-RNA profiling
revealed 49 species of micro-RNA present at higher concentrations in prom1-exo than in parental cells, including 20
with cancer-related function. Extensive accumulation of prom1-exo was observed 3 h after their addition to cultures
of melanoma and bone marrow-derived stromal cells (MSC). Short-term co-culture of melanoma cells and MSC
resulted in heterologous prominin-1 transfer. Exposure of MSC to prom1-exo increased their invasiveness. Our study
supports the concept that specific populations of cancer exosomes contain multiple determinants of the metastatic
potential of the cells from which they are derived.
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Development of effective anti-cancer strategies based on
prevention and targeting of metastatic disease is of high
priority, particularly for melanoma, a disease for which
the development of metastasis is by far the major cause
of patients’ death [1]. Tumor-derived exosomes, small
extracellular vesicles that perform diverse cellular func-
tions including intercellular communication, antigen
presentation, and transfer of proteins, RNA and lipids,
have been recently implicated in the metastatic process.
Exosomes originate by a sequential process of inward* Correspondence: alorico@roseman.edu
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reproduction in any medium, provided the orbudding of late endosomes, producing multivesicular
bodies (MVBs), followed by release of internal microve-
sicles into the microenvironment by fusion of the MVBs
with the plasma membrane [2]. Cancer exosomes may
have a role in the cross-talk between primary tumors
and bone marrow-derived stromal cells (MSC), repro-
gramming MSC and other non-tumor cells to support
local cancer growth as well as to prime pre-metastatic
niche(s) [3-7]. However, difficulties in obtaining homo-
geneous exosomal preparations result in incomplete
understanding of exosome formation, composition and
functions [8]. We recently reported a novel identification
of the extracellular release of prominin-1-containing
membrane microvesicles from human FEMX-I meta-
static melanoma cells, and suggested that prominin-1Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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cells [9]. Our laboratory had previously shown that
prominin-1 knock-down resulted in decreased metastatic
potential of FEMX-I cells in immune-deficient mice [10].
Prominin-1, a pentaspanning transmembrane protein ori-
ginally identified as a surface marker of both neural [11]
and hematopoietic [12] stem and progenitor cells, is
expressed in both established melanoma cell lines and clin-
ical specimens derived from melanoma patients [13-16].
Here, we have employed immune-selection for-
prominin-1 to isolate and characterize a homogenous
preparation of exosomes, presumably engineered from
FEMX-I melanoma cells to perform unique and pro-
metastatic tasks in the local microenvironment.
Experimental procedures
Cell Culture
The human FEMX-I cell line was originally derived from a
lymph node metastasis of a patient with malignant
melanoma [17]. Cells were routinely cultured in RPMI
(Mediatech Inc., Manassas, VA, http://www.cellgro.com)
supplemented with 10% fetal bovine serum (FBS) (Atlanta
Biologicals, Lawrenceville, GA, http://www.atlantabio.
com) at 37°C in a 5% CO2 humidified incubator and used
between passages 3 and 15. Human MSC were obtained
from Dr. Prockop, Texas A & M. They were isolated from
1 to 4-ml bone marrow aspirates taken from the iliac crest
of normal adult donors after informed consent and under
a protocol approved by the Texas A & M Institutional Re-
view Board, prepared as described by Larson et al. [18],
and frozen at passage 1. For expansion, MSC were plated
in a 75-cm2 culture dish, and incubated for 1 day, to re-
cover viable adherent cells. Cultures contained approxi-
mately 50% of rapidly self-renewing cells (RS) and 50% of
larger, more slowly dividing and more mature cells (MS).
MSC were then replated at 50 cells per cm2 and incubated
for 10 days before lentiviral transduction. With time in
culture, the percentage of RS cells decreased progressively
to less of 10% of the total cells. All cell lines were stored in
aliquots in liquid nitrogen and kept in culture for less than
3 months. Complete culture medium for MSC consisted
of α-minimal essential medium (Gibco, Grand Island,
NY), 17% fetal bovine serum (lot selected for rapid growth
of MSC) (Atlanta Biologicals), 100 units/ml penicillin, 100
μg/ml streptomycin, and 2 mM L-glutamine. Cells were
routinely tested for mycoplasma contamination by the
Venor GeM mycoplasma detection kit (Sigma-Aldrich, St.
Louis, MO) and by DAPI staining and authenticated by
morphology check every two weeks.
Preparation of microvesicles and exosomes
For preparation of FEMX-I microvesicles (“classical” prep-
aration) and exosomes (prom1-exo), cells were enzymati-
cally detached and cultured for six days as spheroids inserum-free medium, consisting of Dulbecco’s modified
Eagle’s medium in the presence of B27 supplement (both
from Gibco) in tissue culture plates, as previously de-
scribed [9]. At time of harvest, the pH of the medium was
6.7. “Classical” microvesicle preparations were performed
by differential centrifugation at 4°C at 300 × g for 5 min,
then at 500 × g for 5 min., at 1,200 × g for 20 min. and at
10,000 × g for 30 min, followed by centrifugation at
200,000 × g for 60 min at 4°C. Because these preparations
are likely to contain a mixture of both exosomes and
other microvesicles, we have used the generic term
microvesicles in this study to include the exosome pool.
Prom1-exo were prepared by differential centrifugation at
4°C at 300 × g for 5 min, then at 500 × g for 5 min., at
1,200 × g for 20 min. and at 10,000 × g for 30 min, followed
by filtration with a 0.22 μm low-protein binding Millex-GV
filters (Millipore); the 10,000 × g supernatant was then con-
centrated by Amicon Ultracel-100K (Millipore) tubes
according to the manufacturer’s instructions. The concen-
trate was diluted 1:1 (v/v) with PBS; incubated with anti-
IgG microbeads (Miltenyi Biotec, Auburn, CA) for 90 min
at 4°C, and passed through LS-columns according to the
manufacturer’s instructions. The flow-through was col-
lected, incubated with anti-human-prominin-1 beads
(Miltenyi) for 1 h, and passed through LS-columns. After
washings, the column was removed from the magnet and
prom1-exo were flushed down with 10 ml of cold PBS.
Prom1-exo were then centrifuged at 200,000 g for 60 min
at 4°C and resuspended in PBS. Each exosomal preparation
was checked by nanoparticle tracking analysis for size dis-
tribution and microparticle concentration and by Western
blotting for expression of prominin-1. Exosomes and
microvesicles were stained with PKH67 (Sigma-Aldrich, St.
Louis, MO), according to the manufacturer’s protocol.
Nanoparticle tracking analysis (NTA)
We used the light-scattering characteristics of 488 nm
laser light on microvesicle preparations undergoing
Brownian motion injected by continuous flow into
the sample chamber of an LM10 unit (Nanosight,
Amesbury, UK). Three videos of 60–90 seconds were
recorded of each sample. Data analysis was performed
with NTA 2.3 software (Nanosight). The diffusion coeffi-
cient and hydrodynamic radius were determined using
the Stokes–Einstein equation, and results were displayed
as a particle size distribution. Data are presented as the
average and standard deviation of the three video re-
cordings. Since NTA is most accurate between particle
concentrations in the range of 2 × 108 to 2 × 109/ml,
when samples contained higher numbers of particles,
they were diluted before analysis and the relative con-
centration calculated according to the dilution factor.
Control 100 and 200 nm beads were supplied by
Nanosight. NTA of a small sample of any given
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perse, excluding the problem of aggregation, which may
significantly impact on a biological system.Prominin-1-EGFP fusion plasmid and transfection
We employed the eukaryotic expression plasmid en-
hanced GFP (pEGFP)–N1-prominin-1, containing the
entire coding sequence of human prominin-1 fused
in-frame to the N-terminus of GFP [19], to transfect
FEMX-I cells, as previously described [9].Protein processing and LC-MS/MS
Electrophoresis
Three independent preparations of prom1-exo were ana-
lyzed by LC-MS/MS. Samples, 5 μg each according to
results of Bradford assays, were individually mixed with
20 μl LDS buffer, divided into four fractions and loaded
on NuPage 4–12% Bis-Tris precast gels (Invitrogen,
Carlsbad, CA). Two exterior lanes were loaded with
Sharp pre-stained protein ladder standards (Invitrogen)
and the gel was electrophoresed according the manufac-
turer’s recommendations. Two lanes, one containing
Sharp prestained standards and one containing one
fourth of the total sample, were visualized using a silver
nitrate protocol (QuickSilver, Pierce, Madison, WI), then
realigned with the unstained gel section to create a tem-
plate for excision. The three remaining, unstained lanes
were segmented into 14 equal sections and subjected to
in-gel tryptic digestion following the procedure of
Shevchenko et al. [20]. Briefly, the protocol calls for
reduction with 10 mM DTT and alkylation with 55 mM
iodoacetamide (SIGMA-Aldrich, St. Louis, Mo). Each
segment was prepared with successive wash and dehy-
dration steps using 50 mM ammonium bicarbonate
(AmBic) or 50% acetonitrile containing 50 mM AmBic,
respectively. Finally, the shrunken gel segments were
rehydrated with ice cold AmBic containing 12 ng/ml se-
quencing grade trypsin (Promega, Madison, WI), and
allowed to swell on ice for three hours. Digestions were
then carried out for 16 h at 57°C. The quality of the
digested supernatant was determined prior to lyophi-
lization by spotting 1 μl aliquots mixed 1:1 with a
saturated solution of alpha-cyano-4-hydroxycinnamic
acid (CHCA) acid in 0.1% trifluroacetic acid (Pierce) and
50% acetonitrile onto a stainless steel target plate with
subsequent MALDI/TOF analysis on a Autoflex III
TOF/TOF (Bruker, Billerica, MA). The remainder of the
gel extract was diluted prior to loading on home-brew
StageTips desalting microtip using as previously de-
scribed[21]. Material eluted below 50% acetonitrile
was lyophilized and the concentrated peptides were
rehydrated in 15 μL of 0.1% formic acid with 5% LC/MS-grade acetonitrile and 4uL was used for each LC
injection.
LC-MS/MS analysis
Using a Dionex 3000 nanoRSLC series HPLC system
(Thermo-Electron, Waltham, MA) recovered peptides
were loaded at 2 μl/min onto a 200 μm id by 2.5 cm
precolumn (New Objective, Woburn, MA) packed with
5 μm YMC ODS-C18 beads (Waters, Milford, MA). Fol-
lowing an on-line desalting step, trap flow was rerouted
through a self-packed 75 um id × 9 cm analytical col-
umn containing 3 μm Halo solid-core C-18 particles
with 300 Angstrom pore size. A distal spray opening 8
to 10 microns in diameter restricted the hand-packed
column. A linear gradient from 95% buffer A [0.1% for-
mic acid, 5% acetonitrile and 94.9% LCMS grade water]
to 55% buffer B [90% ACN, 9.9% water and 0.1% FA]
was delivered at 200 μl/min over 70 min using a second
nano-capacity pump. Following this, the composition of
buffer B was ramped to 80% over 5 min, maintained for
5 min and finally decreased to 5% over the final 10 min.
LC effluent was directed to the electrospray source of
a linear ion-trap mass spectrometer (LTQ/XL, Thermo-
Electron, USA). MS/MS spectra were acquired in a data-
dependent acquisition mode that automatically selected
and fragmented the five most abundant peaks from each
MS spectrum. MS.MS scans were recorded in centroid
mode targeting 8000 counts. The trap was filled for a
maximum of 10 ms prior to isolation of the target pep-
tide at an average value 1E04.
Database searching
Tandem mass spectra were processed and charge states
ascertained without deisotoping by Mascot Distiller ver-
sion 2.4. All MS/MS samples were analyzed using batch
processing with the Mascot Daemon interface (version
2.4, Matrix Science) and MASCOT search engine (ver-
sion 2.4 Matrix Science) [21]. All spectral files were also
searched using Spectrum Mill Proteomics Workbench
(Rev.Rev A.03.02.060, Agilent Technologies, Santa Clara,
CA) and X! Tandem (The GPM, thegpm.org; version
CYCLONE (2010.12.01.1)). All three engines were set up
to search SwissProt_2012_09.fasta (selected for Homo
sapiens, Nov. 24 2012, 20,235 entries) assuming the di-
gestion enzyme trypsin and considering up to two
missed cleavages. X! Tandem searches were restricted to
the subset of proteins assigned with either Mascot or
Spectrum Mill.
Mascot, Spectrum Mill and X! Tandem were searched
with a fragment ion mass tolerance of 0.40 Da and a par-
ent ion tolerance of 1.8 Da. Mascot’s Carbamidomethy-
lation of cysteine was specified in Mascot and X!
Tandem as a fixed modification. Oxidation of methio-
nine, carbamidomethylation of lysine were specified in
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tion of methionine was the only variable modification
specified in SpectrumMill.
Criteria for protein identification
Scaffold (version Scaffold_4.0.0, Proteome Software Inc.,
Portland, OR) was used to validate MS/MS based pep-
tide and protein identifications. Peptide identifications
were accepted if they could be established at greater
than 90.0% probability by the Peptide Prophet algorithm
[22]. Protein identifications were accepted if they could
be established at greater than 99.0% probability and
contained at least 4 identified peptides. The Protein
Prophet algorithm as implemented in Scaffold_4.0.0,
assigned protein probabilities [23]. Proteins that contai-
ned similar peptides and could not be differentiated
based on MS/MS analysis alone were grouped to satisfy
the principles of parsimony. Specifically the fragmenta-
tion patterns of distinct peptides from families of
homologous proteins were inspected manually using the
protocol described by Tabb et al. [24]. Hence, validating
at least four unique peptides for each protein listed in-
dividually minimized protein ambiguity. Peptide False
Discovery Rates (FDR) were also estimated using Target:
Decoy search as described by Elias and Gygi [25,26],
with FDR = 2 × (no. of PSM in the decoy)/(No. of all
PSM), where PSM are the peptide spectral matches with
better than 90% probability as described above. The
FDR calculated by this approach, 0.1%, likely benefits
from probabilistically merging multiple search algo-
rithms [23].
Immunoblotting
For immunoblotting, microvesicles and prom1-exo re-
suspended in PBS were checked for consistency by
NTA. Aliquots of microvesicles, exosomes and FEMX-I
total cell lysates containing 1–10 μg of protein were
mixed 1:1 with SDS sample buffer (NuSep, Bogart, GA)
containing 2% 2-mercaptoethanol, boiled for 5 min, and
loaded onto a 8% Tris/Glycine/SDS gel. Electrophoretic
separation of proteins was performed at a constant volt-
age of 120 V for 2 h, and electrophoretic transfer of the
proteins into Hybond ECL membrane (GE Healthcare,
Waukesha, WI) was carried out at constant amperage
(30 mA) for 15 h. The blots were blocked with 5% dry
milk in Tris-buffered saline containing 0.05% Tween 20
(pH 7.5), antibody, and incubated with W6B3C1 anti-
prominin-1 (Miltenyi Biotec, Auburn, CA), or alix 3A9
clone (Cell Signaling Technology, Danvers, MA) at
1:1000 dilution in TBS-T for 5 h at room temperature.
After washing with TBS-T, blots were incubated with
IRDye 800CW secondary antibody (Li-Cor Biosciences,
Lincoln, NE) in TBS-T (1:20,000) for 45 min at room
temperature. Finally, blots were washed with TBS-T,scanned by Odyssey infrared imaging system and analy-
zed by Odyssey 2.1 application software (Li-Cor Biosci-
ences). Gel band densitometric quantification was per-
formed employing the ImageJ64 software (rsbweb.nih.
gov/ij).
ESI-MS/MS lipid profiling
An automated electrospray ionization (ESI)-tandem
mass spectrometry approach was used, and data acquisi-
tion and analysis were carried out as described previ-
ously [27,28] with modifications. The lipid extracts from
the FEMX-I cell pellets were dissolved in 1 ml chloro-
form. An aliquot of 50 μl of each extract in chloroform
was used for analysis. Precise amounts of internal stan-
dards, obtained and quantified as previously described
[29], were added in the following quantities (with some
small variation in amounts in different batches of in-
ternal standards): 0.6 nmol di12:0-PC, 0.6 nmol di24:1-
PC, 0.6 nmol 13:0-lysoPC, 0.6 nmol 19:0-lysoPC, 0.3 nmol
di12:0-PE, 0.3 nmol di23:0-PE, 0.3 nmol 14:0-lysoPE,
0.3 nmol 18:0-lysoPE, 0.3 nmol di14:0-PG, 0.3 nmol
di20:0(phytanoyl)-PG, 0.3 nmol di14:0-PA, 0.3 nmol
di20:0(phytanoyl)-PA, 0.2 nmol di14:0-PS, 0.2 nmol di20:0
(phytanoyl)-PS, and 0.23 nmol 16:0–18:0-PI. The sample
and internal standard mixture was combined with sol-
vents, such that the ratio of chloroform/methanol/300
mM ammonium acetate in water was 300/665/35, and the
final volume was 1.4 ml. The microvesicle samples were
prepared similarly, except that the entire sample was ana-
lyzed, 1/3 of the above standard amounts were added, and
the final volume was 0.75 ml. The unfractionated lipid
samples with internal standards were introduced by con-
tinuous infusion into the ESI source on a triple quadru-
pole MS/MS (API 4000, Applied Biosystems, Foster City,
CA). Samples were introduced using an autosampler (LC
Mini PAL, CTC Analytics AG, Zwingen, Switzerland) fit-
ted with the required injection loop for the acquisition
time and presented to the ESI needle at 30 μl/min. Se-
quential precursor and neutral loss scans of the extracts
produce a series of spectra with each spectrum revealing a
set of lipid species containing a common head group frag-
ment. Lipid species were detected with the following
scans: PC and lysoPC, [M+H]+ ions in positive ion mode
with Precursor of 184.1 (Pre 184.1); PE and lysoPE, [M +
H]+ ions in positive ion mode with Neutral Loss of 141.0
(NL 141.0); PG, [M+NH4]
+ in positive ion mode with NL
189.0 for PG; PI, [M+NH4]
+ in positive ion mode with
NL 277.0; PS, [M+H]+ in positive ion mode with NL
185.0; PA, [M+NH4]
+ in positive ion mode with NL
115.0. SM was determined from the same mass spectrum
as PC (precursors of m/z 184 in positive mode) [27,30]
and by comparison with PC internal standards using a
molar response factor for SM (in comparison with PC) de-
termined experimentally to be 0.39. The collision gas
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gies, with nitrogen in the collision cell, were +28 V for PE,
+40 V for PC (and SM), +25 V for PA, PI and PS, and +20
V for PG. Declustering potentials were +100 V for all
lipids. Entrance potentials were +15 V for PE and +14 V
for PC (and SM), PA, PG, PI, and PS. Exit potentials were
+11 V for PE and +14 V for PC (and SM), PA, PG, PI, PS.
The scan speed was 50 or 100 u per sec. The mass ana-
lyzers were adjusted to a resolution of 0.7 u full width at
half height. For each spectrum, 9 to 150 continuum scans
were averaged in multiple channel analyzer (MCA) mode.
The source temperature (heated nebulizer) was 100°C, the
interface heater was on, +5.5 kV or −4.5 kV were applied
to the electrospray capillary, the curtain gas was set at 20
(arbitrary units), and the two ion source gases were set at
45 (arbitrary units). The background of each spectrum
was subtracted, the data were smoothed, and peak areas
integrated using a custom script and Applied Biosystems
Analyst software, and the data were isotopically decon-
voluted. The first and typically every 11th set of mass spec-
tra were acquired on the internal standard mixture only.
Peaks corresponding to the target lipids in these spectra
were identified and molar amounts calculated in compari-
son to the two internal standards on the same lipid class,
except for PI, which was quantified in relation to a single
internal standard. Ether-linked (alk(en)yl,acyl) lipids were
quantified in comparison to the diacyl compounds with
the same head groups without correction for response fac-
tors for these compounds as compared to their diacyl ana-
logs. To correct for chemical or instrumental noise in the
samples, the molar amount of each lipid metabolite
detected in the “internal standards only” spectra was
subtracted from the molar amount of each metabolite cal-
culated in each set of sample spectra. The data from each
“internal standards only” set of spectra was used to cor-
rect the data from the following 10 samples. Finally, the
data were corrected for the fraction of the sample ana-
lyzed and normalized to the mg protein to produce data
in the units nmol/mg.
miRNA profiling
The miRNA profiling array was carried out using
Applied Biological Materials miRNA profiling service
(ABM C201). Total RNA from FEMX-I cells and
exosomes was prepared byQiazol extraction followed by
poly-A tailing reactions and miRNA cDNA synthesis
(ABM C204). 250 ng of cell’s total RNA and exosomes’
RNA were used in cDNA synthesis. Both cells’ and
exosomes’ cDNA synthesis were carried out simultan-
eously and equal volume of cDNA synthesis reaction
product was used in the subsequent profiling. The Ct
values for each miRNA-specific cDNA were compared
between FEMX-I cells and exosomes. Real-time qPCR
reactions and instrumental analysis was performed usingRoche LightCycler480. Lists of miRNAs were generated
by pair-wise comparison of our expression data sets
(cells vs exosomes). Differentially expressed miRNAs
were analyzed by the Ingenuity Pathway Analysis soft-
ware (Ingenuity Systems, Redwood City, CA) to identify
the biological functions that were most significant to the
data sets.
Immunofluorescence
Cells were seeded on poly-L-lysine coated chamber
slides and grown overnight. Following aspiration of
media, cells were fixed in 4% paraformaldehyde (PFA),
washed with PBS, permeabilized in 0.5% Tween 20 and
blocked with goat serum. After washing with PBS, cells
were incubated overnight at 4°C with primary antibodies
in 1% BSA-PBS, followed by washes and a 45-minutes
incubation at room temperature with fluorochrome-
labeled secondary antibody in 1% BSA in PBS. Fluo-
rescent cells were analyzed by a CKX41 fluorescence
inverted microscope (Olympus, Center Valley, PA).
Invasion assay
In vitro invasion assays were performed in BioCoat inva-
sion chambers holding matrigel-coated-8 μm-pore PET
membrane cell culture inserts, using non-coated inserts
as control (both from BD Biosciences, San Jose, CA),
according to the manufacturer's directions. The matrigel
layers of the invasion chambers were rehydrated with
serum-free medium. The lower chambers were filled
with medium containing 2% FBS, and equal aliquots of
cells, pre-incubated for 3 h with or without prominin-1
-purified exosomes, were added in serum-free medium
to the inserts. Following 24 h incubation at 37°C, the
cells on the upper side of the membrane were gently re-
moved with wet sterilized cotton swabs. The cells on the
lower surface of the membranes were fixed with 4%
para-formaldehyde for 10 min, and then stained with
DAPI. The number of cells was counted in 8–12 ran-
domly selected 10X-microscopic fields per insert using
an Olympus CKX41 fluorescence microscope (Olympus
America Corp., Center Valley, PA), and matrigel inva-
siveness expressed as the percentage of the number of




We previously reported that human FEMX-I metastatic
melanoma cells released into the extracellular medium
prominin-1-expressing microvesicles [9]. To investigate
their nature, we cultured FEMX-I cells as spheroids
under serum-free conditions for six days and compared
a “classical” microvesicle preparation, based on differen-
tial centrifugation [9], with a prominin-1+ preparation,
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differential centrifugation, filtration and prominin-1-
based immuno-magnetic selection (prom1-exo). The
final pH at time of harvest was 6.7, which resembled
in vivo tumor growth conditions, where low pH condi-
tion is a hallmark of tumor malignancy, particularly for
malignant melanoma cells, which, differently from nor-
mal cells, can survive in an acidic microenvironment
[31]. Low pH conditions reportedly increase exosome
release and uptake by cancer cells [32]. We used serum-
free medium in the present study because serum supple-
ments (such as fetal calf serum) often contain vesicles as
well as aggregates of serum proteins, which may interfere
with the isolation and characterization of FEMX-I
exosomes. By NTA, we determined both size distribution
and relative concentration of microvesicles and prom1-
exo in the supernatants of FEMX-I cells. As shown by
NTA of PKH67-stained microvesicles, the “classical”
microvesicle preparation showed several peaks, ranging
from 70 to 550 nm, while prom1-exo yielded a single peak
of about 100 nm (Figure 1B); persistent binding of anti-
prominin-1 50 nm-immunomagnetic beads resulted in an
apparent over-estimation of the exosomal size and broad-
ening of the size distribution peak. The concentration of
microvesicles and prom1-exo in FEMX-I supernatant
were 3 ± 0.4 ×109/ml and 0.35 ± 0.2 × 109/ml, respectively.Figure 1 Isolation and characterization of prom1-exo from FEMX-I ce
centrifugation and of prom1-exo by a combination of differential centrifug
tracking analysis shows size distribution of a “classical” ultracentrifugation-b
immunomagnetic preparation (prom1-exo), both from serum-free culture m
preparations were stained with the membrane dye PKH67 and fluorescenc
intensities of 80 and 120 nm for microvesicles and 90 nm for exosomes, re
prominin-1 microvesicles resulted in an over-estimation of their size distribWe then employed the same methodology (Figure 1A) to
investigate whether it was possible to isolate prom1-exo
from different prominin-1-expressing cancer cell lines.
We found that prominin-1-immunomagnetic selection
resulted in isolation of cancer exosomes also from human
prominin-1-expressing Caco-2 colon carcinoma cells
(Figure 1B). An approximately 10-fold difference in con-
centration of microvesicles and prom1-exo was found also
in the cell supernatants of Caco-2 cells (1.5 ± 0.35 × 109/ml
and 0.18 ± 0.05 × 109/ml, respectively). Similarly to what
we observed in FEMX-I cells, Caco-2 cells microvesicles
had a broad size range, while prom1-exo had a single
100 nm-peak.
Proteome of prominin-1+ microvesicles
Comparison of total cell lysates, microvesicles and
prom1-exo from FEMX-I cells by Western blotting
(Figure 2) revealed a great enrichment in prominin-1
and in the exosomal protein alix in prom1-exo vs. the
FEMX-I cells themselves (53- and 184-fold for promi-
nin-1 and alix, respectively) and vs. microvesicles
(78- and 168-fold for prominin-1 and alix, respectively).
To investigate whether they had the biochemical charac-
teristics of bona fide exosomes, we analyzed the
proteolipidic composition of prom1-exo from FEMX-I
cells. Three independent preparations were used tolls. A. Scheme of isolation of “classical” microvesicles by differential
ation, filtration and immuno-magnetic separation. B. Microvesicle
ased preparation of microvesicles and a prominin-1-based
edium of the human FEMX-I metastatic melanoma cell line. Both
e analyzed by a 488 nm laser. Nanotracking analysis gives mean peak
spectively. The persistent binding of magnetic beads (50 nm) to the
ution.
Figure 2 Enrichment of prominin-1 and alix in prom1-exo. Immunoblotting analysis of total cell lysates, microvesicles (MVs), and prom1-exo
from FEMX-I cells. 1 and 10 μg of total proteins were loaded per lane for total cell lysates and MVs and 1 μg for prom1-exo, and analyzed as
described under Experimental Procedures.
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spectrometry (see search methods in Additional file 1:
Table S1). A total of 282 proteins were confidently
assigned across all three samples (Additional file 2:
Table S2 and Additional file 3: Table S3). We further
highlighted an ensemble of proteins among which could
be verified with two or more stringent peptide spectral
matches (PSM) in all three replicates or those observed
with three or more stringent PSM in any two replicates
(Additional file 4: Table S4). This subset of 154 proteins
is highly enriched for physiological processes (Additional
file 5: Figure S1), involving membrane bound vesicles
[count 40, p-value 6.4E-21] and endocytosis [count 20,
p-value 7.3E-11] complexes, and including all of the 14
proteins most expressed in exosomes according to the
compilation of peer-reviewed data hosted on the
Exocarta site [33] (Table 1). Since the biogenesis of
exosomes takes place in late endosomes to end up in
multivesicular bodies (MVB), we first checked our list of
proteins for those known to be involved with that
particular compartment (Table 2). Reassuringly, we
identified the bro1 domain-containing proteins alix andTable 1 Prom1-exo composition includes all the 14 most-expr
Protein name Gene symbol Acce
Heat shock cognate 71 kDa protein HSPA8
CD9 Antigen CD9
Glyceraldehyde-3-phosphate dehydrogenase GAPDH





Heat shock protein HSP 90-alpha HSP90AA1
Elongation factor 1-alpha 1 EEF1A1
Pyruvate kinase isozymes M1/M2 PKM
14-3-3 protein epsilon YWHAE
Syntenin-1 SDCBP
Programmed cell death 6-interacting protein PDCD6IPbrox, known to function in association with the ESCRT
(Endosomal Sorting Complex Required for Transport)
pathway to help mediate intraluminal vesicle formation at
multivesicular bodies and the abscission stage of cytokin-
esis. Various ESCRT components, central to MVB biogen-
esis, were identified in prom1-exo, including five ESCRT-I
proteins [34], three ESCRT-III proteins and many other
ESCRT-associated proteins (Table 2). Other proteins, re-
lated to their endosomal origin, were identified, including
membrane transport and fusion proteins (GTPases,
Annexin A2, A4, A5, A6 and A11); eight tetraspanins
(TSPAN 4,6,9,14; CD63; CD81; CD82; CD9), and five Rab
proteins (Additional file 4: Table S4). Interestingly,
the immunosuppressive Immunoglobulin superfamily
member 8 (IgSF8), also named CD81 partner 3,
known to interact with CD81, CD9 and CD82 as well
as with integrin alpha-3/beta-1 and integrin alpha-4/
beta-1, was highly expressed. The absence of endo-
plasmic reticulum proteins, such as calnexin and
Grp78, and of Golgi proteins, such as GM130, indi-
cated no contamination of vesicles of other compart-
ments in prom1-exo preparations.essed exosomal proteins (Exocarta)




























ESCRT-I VPS-28 Q9UK41 9 57
VPS-37B Q9H9H4 9 55
FAM125A Q96EYS 6 37
FAM125B Q9H7P6 5 38
TSG101 Q99816 13 37
ESCRT-III CHMP2A O43633 3 16
CHMP4B Q9H444 6 35
CHMP5 Q9NZZ3 4 31
ESCRT-associated
proteins
Brox Q5VW32 10 40
PDCD6IP Q8WUM4 63 75
VPS-4A Q9UN37 9 22
MITD1 Q8VW92 6 36
IST1 P53990 11 33
HSPA1A P08107 17 46
HSPA8 P11142 46 75
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http://www.molecular-cancer.com/content/12/1/62Other cancer-related proteins and/or proteins impli-
cated in cancer progression were identified, including
CD44 [35], Hsp70 [36], annexin A2 [37-40], as well as
components involved in Wnt (SFRP1 = secreted frizzled-
related protein 1) and Ras signaling, including the GTP-
binding proteins Rap1b and Rap2b, reportedly involved
in the activation of ERKs [41], the 14-3-3 protein, a
family of exosomal proteins that have a matrixFigure 3 Co-localization of prominin-1 with CD29 in FEMX-I cells. Inse
represent areas of peri-nuclear co-localization of prominin-1 and CD29. Prometalloproteinase-1 stimulating effect for dermal fibro-
blasts [42], and disintegrin and metalloproteinase
domain-containing protein 10 (ADAM 10) (Additional
file 4: Table S4). A perinuclear pool of prominin-1, asso-
ciated with integrin-beta 1 (CD29), expressed in FEMX-I
exosomes, was detected by fluorescence microscopy
(Figure 3). Interestingly, a striking correspondence be-
tween prominin-1 and CD29 in FEMX-I cells was ob-
served, suggesting their co-localization in endosomal
compartments.
Prom1-exo have a typical lipid raft composition
A lipid composition analysis of prom1-exo and parental
FEMX-I cells was performed through ESI MS/MS
(Figures 4 and 5). A typical lipid raft composition of
prom1-exo was observed, with 400% increase in sphingo-
myelin, 240% increase in phosphatidylserine, 290% in
phosphatidylglycerol, 2150% in lyso-phosphatidylethanol-
amine) and 1190% in lyso-phosphatidylchoxline. A great
number of membrane lipids were significantly different
between prom1-exo and the membrane compartment of
parental FEMX-I cells (Table 3). To offset the elevated
sphingolipid levels, phosphatidylcholine levels were de-
creased by 26%, resulting in similar choline-containing
lipid levels between prom1-exo and the FEMX-I plasma
membrane. A 45% decrease in phosphatidylinositol
content of prom1-exo also partially accounted for the
observed increase in raft-associated lipid species of
the exosomes.
Specific “loading” of miRNAs in prom1-exo
The miRNA “cargo” of prom1-exo was significantly
different from the parental cell content. Of the 1,058ts in the upper panels were enlarged in the lower panels. Arrows
minin-1, red. CD29, green; DAPI, blue. Bars, 25 μm.
Figure 4 Different membrane lipid distribution between parental FEMX-I cells and prom1-exo. An automated ESI-tandem mass
spectrometry approach was used. The lipid extracts from cells and microvesicles were dissolved in 1 ml chloroform. An aliquot of 50 μl of each
extract in chloroform was used for each analysis. To correct for chemical or instrumental noise in the samples, the molar amount of each lipid
metabolite detected in the “internal standards only” spectra was subtracted from the molar amount of each metabolite calculated in each set of
sample spectra. The data from each “internal standards only” set of spectra was used to correct the data from the following 10 samples. Finally,
the data were corrected for the fraction of the sample analyzed and normalized to the mg protein to produce data in the units nmol/mg. Data
are presented as percent of total lipids analyzed. *, p < 0.05; **, p < 0.01 (unpaired Student’s t test). SM-DSM, sphingomyelin-dihydro
sphingomyelin; PS, phosphatidylserine; PG, phosphatidylglycerol; e-PE, ether-linked phosphatidylethanolamine; e-PC, ether-linked
phosphatidylcholine; PI, phosphatidylinositol; PA, phosphatidic acid.
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http://www.molecular-cancer.com/content/12/1/62miRNA species investigated, only 49 were over-
expressed in prom1-exo (Table 3), including miRNAs
known to mediate immune tolerance, and 13 cancer/
metastasis-associated miRNAs. In particular, miR-216b,
a well-known tumor and metastasis suppressor mi-
RNA, that targets Ras [43,44], was highly expressed in
prom1-exo and undetectable in FEMX-I cells, indicat-
ing a detoxification role for prom1-exo; let-7i, associ-
ated with metastatic progression [45-47], was found to
be expressed at levels 53-fold higher in prom1-exo
than in FEMX-I cells. Also, miR-10a, reportedly in-
volved in the metastatic process and immune-escaping
[48,49] was 3.2-fold higher in prom1-exo than in par-
ental cells.
Transfer of prom1-exo to adjacent FEMX-I and MSC
Exposure of FEMX-I cells to PKH-67-labeled prom1-exo
for 3 h resulted in massive green perinuclear fluores-
cence (Figure 6A), co-localized with the red fluorescence
of the intracellular pool of prominin-1 upon incubation
of the cells with phycoerythrin-conjugated monoclonals
(Figures 6A and 3A-B). Interestingly, also exposure of
human MSC to PKH-67-labeled prom1-exo for 3 h
resulted in intra-cellular localization of fluorescent
prom1-exo and of prom1-exo-associated prominin-1
(Figure 6A); for MSC, the punctate pattern differed from
the perinuclear accumulation for FEMX-I cells,presumably for the lack of an endogenous pool of
prominin-1 in MSC. Since a shorter (1 h)-exposure of
FEMX-I to PKH-67-labeled prom1-exo resulted in ex-
clusive, although minor, perinuclear accumulation of
green fluorescence (data not shown), the complete ab-
sence of puncta in FEMX-I cells may be due to the rapid
kinetics of intracellular exosome trafficking or turnover.
To confirm the intracellular delivery of prominin-1 by
prom1-exo, MSC were incubated with prom1-exo pre-
pared from FEMX-I cells transiently transfected with a
prominin-1-GFP fusion plasmid. After 3 h, extensive
fluorescence from prominin-1-GFP was detected in
the intracellular compartment of MSC (Figure 6B),
confirming that prominin-1 was effectively delivered to
MSC. To investigate whether direct transfer of prom1-
exo occurred from FEMX-I to MSC in mixed cultures,
we co-cultured the cells at 5:1 ratio (FEMX-I:MSC) for
24 h, and analyzed the expression of prominin-1 by im-
munofluorescence. Figure 6 clearly shows transfer of
prominin-1 from FEMX-I to the intracellular compart-
ment of MSC. The apparent contrast between the
massive uptake of exosomes in Figure 6 and the rela-
tively low transfer of exosomes from FEMX-I to MSC
in Figure 7 may be explained by the technical diffe-
rences of the two experiments (sudden addition of
exosomes in Figure 6 and gradual release of exosomes
in Figure 7).
Figure 5 Differences in lipid profiling between prom1-exo (MV)
and parental FEMX-I cells (FEMX). An automated ESI-tandem mass
spectrometry approach was used for lipid profiling. Averages of
three to five determinations for each sample group were calculated.
Red, lipid species over-expressed in prom1-exo; blue, lipid species
over-expressed in parental FEMX-I cells. *, p < 0.05; **, p < 0.01; ***,
p < 0.001 (unpaired Student’s t test); head groups: PS, phosphatidyl
serine; PE, phosphatidylethanolamine; PC, phosphatidylcholine; PI,
phosphatidylinositol; the first number indicates the length of the
hydrocarbon chain and the second number indicates the number of
double bonds.
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http://www.molecular-cancer.com/content/12/1/62Effects of exosomes on MSC invasiveness
We then investigated whether exposure of MSC to
prom1-exo resulted in biological effects, such as changes
in their invasiveness, measured by the capacity of MSC to
pass through a Matrigel layer. Interestingly, a 90% increase
in Matrigel invasion was observed after a standard 24 h-
assay, compared with mock-treated MSC (Figure 8).
Discussion
Building on our previous finding of a pro-metastatic role
of prominin-1 in melanoma [9], we have here isolated
from in vitro serum-free cultures of FEMX-I melanoma
prominin-1-expressing exosomes. This is the first report
of prominin-1-based purification of cancer exosomes.
The prominin-1-based exosomal isolation protocol was
then successfully employed to isolate exosomes from the
serum-free culture medium of another prominin-1-ex-
pressing cancer cell line, Caco-2 colon carcinoma. Inter-
estingly, Tauro et al. [50] recently reported the isolation,
via sequential immunocapture using anti-A33- and
anti-EpCAM-coupled magnetic beads, of prominin-1-ex-
pressing exosomes from the human colon carcinoma cell
line LIM1863.
Consistent with findings of other groups in different
experimental models [51,52], a specific sorting of pro-
teins, lipids and microRNA was observed in in prom1-
exo. Preparations of exosomes from biological fluids and
in vitro cell cultures using a variety of strategies and
techniques have been extensively reported by many
groups; however, the great majority of preparations con-
tain varying proportions of other membranous vesicles
that co-purify with exosomes, such as shed microvesicles
and apoptotic blebs [8,33]. The importance of analyzing
purified exosomal preparations is evident if we consider
that although exosomes, due to their small size (40–100
nm), are expected to contain less than 150 proteins, to
date over 4,500 proteins have been identified in
exosomes from multiple organisms (http://exocarta.org).
While some of these proteins are considered tissue-
specific, many can be considered preparation contami-
nants. The fact that prom1-exo present respectively a
78- and 168-fold higher concentration of prominin-1
Table 3 List of miRNAs over-expressed in prom1-exo
compared with parental FEMX-I cells




hsa-miR-216b >40 15.81 24.2 19138839.3
hsa-miR-889 37.33 15.86 21.47 2910427.1
hsa-miR-4307 >40 22.51 17.5 184083.4
hsa-miR-4272 >40 22.99 17 131983.7
hsa-miR-203 >40cyclcs 23.82 16.2 74244.7
hsa-miR-4289 23.34 8.67 14.66 25944.3
hsa-miR-3149 22,7 8.77 13.94 15746.0
hsa-miR-203 26.41 13.69 12.72 6769.4
hsa-miR-3145 21.19 10.53 10.66 1622.1
hsa-miR-1911 >40 29.72 10.3 1243.3
hsa-miR-513a-3p >40 29.84 10.2 1144.1
hsa-miR-3916 >40 30.52 9.48 714.1
hsa-miR-886-3p >40 32.31 7.69 206.5
hsa-miR-1182 22.77 15.91 6.86 115.1
hsa-miR-3613-5p >40 33.69 6.31 79.3
hsa-let-7i 22.95 17.21 5.73 53.2
hsa-miR-3132 16.50 11.49 5.01 32.2
hsa-miR-3914 24.75 20.39 4.36 20.5
hsa-miR-3618 28.56 24.35 4.21 18.5
hsa-miR-1307 21.87 17.96 3.91 15.0
hsa-miR-3614-3p 21.90 19.15 2.75 6.7
hsa-miR-519c-3p 22.59 20.22 2.3k 5.2
hsa-miR-3160 17,61 15.28 2.33 5.0
hsa-miR-3153 11.48 9.53 1.96 3.9
hsa-miR-4278 18.94 16.99 1.95 3.9
hsa-miR-3646 I.58 15.80 1.79 3.5
hsa-miR-3926 17.47 15.72 1.75 3.4
hsa-miR-515-5p 28.37 26.69 1.68 3.2
hsa-miR-3169 14.33 12.67 1.66 1.2
hsa-miR-10a 31.87 30.21 1.66 3.2
hsa-miR-140-5p 26.92 25.37 1.55 2.9
hsa-miR-3148 18.74 17.56 1.18 2.3
hsa-miR-4271 17.56 16.48 1.08 2.1
hsa-miR-627 23.07 22.00 1.07 2.1
hsa-miR-548d-3p 29.69 28.66 1.03 2.0
hsa-miR-3613-3p 22.09 21.19 0.90 1.9
hsa-miR-481 26.49 25.64 0.85 1.8
hsa-miR-571 20.81 19.97 0.84 1.8
hsa-miR-4274 19.93 19.15 0.79 1.7
hsa-miR-4277 21.41 20.79 0.62 1.5
hsa-miR-3686 15.41 14.81 0.61 1.5
hsa-miR-3074 21.65 21.10 0.54 1.5
hsa-miR-95 24.90 24.45 0.46 1.4
Table 3 List of miRNAs over-expressed in prom1-exo
compared with parental FEMX-I cells (Continued)
hsa-miR-590-3p 26.81 26.49 0.32 1.2
hsa-miR-525-5p 23.20 22.90 0.30 1.2
hsa-miR-548g 26.97 26.69 0.28 1.2
hsa-miR-365 25.46 25.18 0.28 1.2
hsa-miR-525-3p 23.23 22.94 0.28 1.2
hsa-miR-320d 21.97 21.93 0.04 1.0
Total RNA from FEMX-I cells and exosomes was prepared with Qiazol
extraction followed by poly-A tailing reactions and miRNA cDNA synthesis. 250
ng of cell’s total RNA and of exosomes’ RNA were used in cDNA synthesis.
cDNA synthesis were carried out simultaneously and equal volume of cDNA
synthesis reaction product was used in the subsequent real-time qPCR
reactions. 1058 miRNAs were investigated. The DeltaCt (DCt) values for each
miRNA-specific prom1-exo cDNA greater than 0.01 were listed.
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http://www.molecular-cancer.com/content/12/1/62and alix compared with microvesicles derived from the
same cell line, as well a striking concentration of certain
classes of microRNA, indicates that prom1-exo consti-
tute an homogeneous species of exosomes, loaded with
a pro-metastatic cargo.
It is now becoming clear that, when a complex
message needs to be sent to surrounding cells in the
microenvironment, cells use exosomes, which have the
advantage, compared to other means of intercellular
communication, to target multiple specific locations in-
side the target cell(s), based, at least in part, on the spe-
cific Rab proteins expressed, which act as mailing tags
to distribute exosomes to the correct intracellular com-
partment. The presence of 5 distinct Rabs (Rab 5B, Rab
5C, Rab 7A, Rab 8A and Rab 10) suggests that prom1-
exo are destined to different endosomal compartments
in the host/target cell. For example, Rab 5C, 7A and 8A
are indispensable effectors/constituents of early endoso-
mes, late endosomes, and secretory endosomes, respect-
ively [53,54]. Herein, we have clearly shown rapid
uptake of prom1-exo into neighboring FEMX-I cells
and MSC, associated with intracellular delivery of
prominin-1. Our finding that prom1-exo contain pro-
teins involved in the ESCRT complex suggests that,
once they reach their target cell(s), prom1-exo are able
to be endocytosed into the endosomal system of recipi-
ent cells and deliver their “cargo” into the cytoplasm as
a reversal mechanism of their formation process. Inter-
estingly, the presence in prom1-exo of the “fusogenic”
proteins CD9, CD63, CD81, ADAM 10, GTP-binding
protein α13 and RhoA [55-59] suggests also an alter-
native mechanism of “cargo” delivery, i.e. receptor-
mediated fusion with the plasma membrane of the host
cell(s).
The presence of both syntenin-1 and alix in prom1-
exo supports a recent theory of the biogenesis of
intraluminal vesicles (ILVs) and exosomes [60], while the
presence of two heat shock proteins, hsp70 and hsc70
Figure 6 Uptake of prom1-exo by FEMX-I and MSC. A. Cells
were incubated for 3 h with PKH67-labeled green fluorescent
prom1-exo, fixed and stained with phycoerythrin-conjugated AC133
anti-prominin-1 antibody. Arrows represent areas of co-localization
of green PKH67 fluorescence and red fluorescent anti-prominin-1
antibodies. Since MSC do not express prominin-1, there could be no
interference from an endogenous MSC prominin-1 pool. Bars, 25
μm. B. MSC were incubated for 3 h with prom1-exo prepared from
FEMX-I cells transiently transfected with a prominin-1-GFP
fusion plasmid.
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http://www.molecular-cancer.com/content/12/1/62and of the hsc-70 co-chaperone dj2 [61] is in agreement
with their function in endosomal cargo selection and in
general as molecular chaperones, limiting protein aggre-
gation, and facilitating protein refolding. Our data are
consistent with the previous finding of secretion of
heat shock proteins into the circulation via lipid
raft-mediated, or exosome-mediated exocytosis in tumor
cells [62]. Interestingly, the high level of expression of
IgSF8, known to have an immunosuppressor role, by
inhibiting T-cell mobility coordinately with CD81 [63],
and the finding by other groups that extracellular HSPs
exert immunomodulatory activities [62] suggest an im-
portant role of prom1-exo in the immune escape of
FEMX-I melanoma.
Several tetraspanins were identified in prom1-exo.
Many members of the tetraspanin family, the most
abundant protein family found in exosomes [33], includ-
ing most of the tetraspanins present in prom1-exo, regu-
late cell migration, fusion, and signaling events by theirrecruitment into special membrane microdomains and
their abundant presence in microvesicles that mediate
intercellular communication [64]. Interestingly, tetraspa-
nins organize other proteins through intra- and inter-
molecular interactions into a multimolecular tetraspanin
enriched microdomains (TEMs), which, in association
with other proteins and lipids, such as cholesterol and
sphingomyelin [65], forms the extended network of
tetraspanin interactions in the membrane, commonly
described as tetraspanin web [66]. Our findings of co-
expression of many tetraspanins and of a 4-fold increase
in sphingomyelin supports the concept that tetraspanin
webs are building blocks of prom1-exo.
By ESI/MS-MS lipid profiling, we found that typical raft
components were associated with prom1-exo. The fact
that other cancer cell types secrete exosomes containing
similarly organized lipid subdomains [51,67], suggests that
lipid rafts may play a general role in exosome biogenesis
and structure, especially sphingolipids, known to play a
key role in the genesis of exosomal MVBs [68], and
phosphoglycerides with long and saturated fatty-acyl
chains [67-69]. Our data also support the hypothesis
that the lipid raft composition of endosomes, of which
exosomes represent an extracellular mirror, allows them
to be multi-purpose platforms [70].
As proposed for hematopoietic and neural stem cells
[71,72], prominin-1 may have a specific role in intercel-
lular communication via exosomes, and protein–lipid
assemblies might be the essential structural determinant
in the release process of prominin-1 by stem and cancer
stem cells. In addition, the full molecular characterization
of prom1-exo described here supports the concept of
‘cancer stem cell-specific lipid rafts’ holding molecular
determinants necessary to maintain cancer stem cell/
pro-metastatic properties [72]. Interestingly, the high
sphingomyelin and phosphatidylserine content of prom1-
exo may lead to their capacity to fuse with the plasma
membrane of host cells and enter the intracellular com-
partment [32]. In fact, lipid rafts reportedly [73] affect
protein binding and modulate membrane physicochemi-
cal and mechanical properties: thus, sphingomyelin-
enriched microdomains modulated the efficiency of
membrane fusion [74], and annexin V blockade of
phosphatidylserine on the surface of exosomes prevented
exosome uptake into microglia [75].
The 21.5-fold increase in lyso-phosphatidylethanol-
amine observed in prom1-exo may contribute to the
pro-metastatic phenotype of FEMX-I cells, in light of
the report by Park et al. [76] that lyso-phosphatidyletha-
nolamine treatment of SK-OV3 ovarian cancer cells
results in chemotactic migration and cellular invasion.
However, whether this mechanism or the transfer
of metalloproteinases, such as ADAM10, present in
prom1-exo, is responsible for the increased invasiveness
Figure 7 Co-culture of MSC and FEMX-I cells shows uptake of prominin-1 by MSC. MSC and FEMX-I cells were cultured for 24 h at 1:5 ratio.
After fixation and permeabilization, expression of prominin-1 was analyzed by immunofluorescence employing phycoerythrin-conjugated AC133
anti-prominin-1 antibody. Since MSC do not express prominin-1, there could be no interference from an endogenous MSC prominin-1 pool.
Insets in the upper panels were enlarged in the lower panels. Arrows indicate some areas of prominin-1 positivity inside a MSC. Red, prominin-1;
blue, DAPI. Bars, 25 μm.
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http://www.molecular-cancer.com/content/12/1/62of MSC upon exposure to prom1-exo can not be con-
cluded from the present study.
Consistent with other previous studies [77-79], a con-
siderable difference in the miRNA profile of cancer
exosomes and the originating cancer cells was observed
in the present study. Specifically, 49 miRNA were found
to be over-expressed in prom1-exo, including miRNAs
known to mediate immune tolerance, and 13 cancer/me-
tastasis-associated miRNAs. This is in apparent contrast
with the claim from several authors [80,81] that the
miRNA content of circulating exosomes is similar to
that of the originating cancer cells. The cancer-
associated loss of miRNA expression often leads to a
proliferative advantage and aggressive behavior through
largely unknown mechanisms. The finding of very high
levels of miR-216b in prom1-exo, coupled with un-
detectable levels in parental FEMX-I cells, is intriguing
in light of reports that miR-216b suppresses tumor
growth and invasion by targeting KRAS in nasopharyn-
geal carcinoma [43] and inhibits cell proliferation and
colony formation through Ras inhibition in a pancreatic
cancer model [44]. Similarly, a 53-fold lower level of
let-7i was observed in FEMX-I cells compared with
prom1-exo. Since underexpression of let-7i was found to
characterize metastatic progression of oral carcinoma
[45] and to have a crucial role in colorectal cancermetastasis [46], it is conceivable that exosomal removal
of both miR-216b and let-7i from the intracellular com-
partment plays a significant role in the malignant pheno-
type of FEMX-I melanoma. While removal of some
species of microRNAs may have a detoxification role,
exosomal delivery of other species of microRNA, such as
miR-10a, to other cells in the microenvironment may
play an important role in FEMX-I melanoma immuno-
escape. In fact, miR-10a, present in prom1-exo at levels
3.2-fold higher than in parental cells, was recently shown
to attenuate the phenotypic conversion of inducible T
(reg) cells into follicular helper T cells and limit differen-
tiation into the T(H)17 subset of helper T cells [48].
Also, miR-10a reportedly stimulates cell invasion,
suggesting a potential mechanism for the pro-invasive
effect of prom1-exo on MSC [49]. Therefore, prom1-exo
may accomplish for FEMX-I melanoma cells a double
role of cell detoxification via excretion and of modula-
tion of the function of other cell types, in particular
MSC, in the microenvironment. Our data, suggesting a
pro-malignant role of prom1-exo, are consistent with a
recent report by Peinado et al. [7] that exosomes from
highly metastatic melanomas increased the metastatic
behavior of primary tumors by permanently ‘educating’
bone marrow progenitors through the receptor tyrosine
kinase MET. To metastasize, tumor cells need to send
Figure 8 Enhanced invasiveness of MSC through matrigel
induced by prominin-1-purified exosomes. In vitro invasion
assays were performed in BioCoat invasion chambers holding
matrigel-coated-8 μm-pore PET membrane cell culture inserts, using
non-coated inserts as control. The lower chambers were filled with
medium containing 2% FBS, and equal aliquots of MSC, pre-
incubated with or without prominin-1-purified exosomes, were
added in serum-free medium to the inserts. Following 24 h
incubation at 37°C, as recommended by the manufacturer, the cells
on the upper side of the membrane were gently removed with wet
cotton swabs. The cells on the lower surface of the membranes
were fixed with 4% para-formaldehyde for 10 min, and then stained
with DAPI. Matrigel invasiveness is expressed as the percentage of
the number of matrigel-invading cells respect to the control of
chemotactic migration. Columns, mean values of three separate
experiments; bars, SD; *p < 0.05, unpaired Student’s t test.
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http://www.molecular-cancer.com/content/12/1/62complex messages intended to subvert the normal func-
tion of their immediate neighbors, fertilize vascu-
logenesis and find or recruit a susceptible berth.
However, messages of all sorts are being identified in
many functional exosomal studies, and if we sample
them stochastically it will be difficult to see the whole
picture. Prom1-exo, homogenous cancer organelles ex-
pressing a cancer stem cell marker, are more likely to
have a concordant message(s), and this makes them es-
pecially interesting to gain insight into the mechanisms
by which exosomes contribute to the malignant pheno-
type. In addition, our characterization of prom1-exo
from FEMX-I cells may be employed as a model for in-
vestigating the rules that govern the formation of mem-
brane microdomains: in contrast to rafts, exosomes are
remarkably stable structures that can be purified without
the intervention of destructive techniques such as deter-
gents or ultrasounds. Our model, therefore, in additionto allowing progress in the understanding of the role(s)
of cancer-derived exosomes in the metastatic process,
can also shed light on the natural process of selective
proteolipidic sorting in biological membranes and traf-
ficking in living cells. Further studies are warranted to
determine what part of their cargo and which molecular
mechanisms exosomes, and in particular prom1-exo,
utilize to modify the phenotype of the different cells in
the local tumor microenvironment and exert specific
roles in the metastatic phenotype.Additional files
Additional file 1: Table S1. Search conditions for proteomic LC-MS/MS
data sets. MS/S data was acquired during 70 min gradients run on hand-
packed capillary columns as described in Materials and Methods. The
effluent was interfaced to an ESI source and peptides were recorded
with data-dependent scanning using a top 5 method on an LTQ/XL ion
trap (Thermo). Table 1 describes data processing, search conditions
common to both the MASCOT and Spectrum Mill Proteomics
Workbench applied in this work as well as particular features of the
SwissProt database used.
Additional file 2: Table S2. Protein assignments. Use of the Peptide
and Protein Prophet algorithms to condense independent searches of
the same data sets provided 282 proteins (including keratins) across a
total of three biological isolations of prom1-exo with an FDR of 0.1%, a
minimum of three peptides and a protein sensitivity of 99%. Additional
file 2 lists proteins matching these criteria.
Additional file 3: Table S3. All Peptides attributed to proteins from
Additional file 2. All peptides identified in three replicate isolations of
prom1-exo. Scaffold 4.0.0 was used to rescore the results of MASCOT
and SpectrumMill searches. Scaffold generates an adaptive discriminate
scoring using Peptide and Protein Prophet algorithms. Complete results
are listed in Additional file 3: Table S3.
Additional file 4: Table S4. Selection of the most observable proteins
associated with prom1-exo. Tables 1 and 2 of the manuscript illustrate
protein enrichment for physiological processes involving endosome and
ESCRT complexes. These proteins are highlighted among an ensemble
verified with two or more stringent peptide spectral matches (PSM) in all
three replicates or those observed with three or more stringent PSM in
any two replicates. Additional file 4: Table S4 is a complete list of these
154 proteins.
Additional file 5: Figure S1. Enrichment for physiological processes of
the most observable proteins associated with prom1-exo.Abbreviation
Prom1-exo: Prominin-1-expressing exosomes; MSC: Bone marrow-derived
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VPS: Vacuolar protein sorting; ESCRT: Endosomal sorting complex required
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